GLP1R and chronic kidney disease: Hence, the final results of the above two studies appear to be influenced by the neutral cardiovascular effects of exenatide (HR: 0.91; 95% CI: 0.83-1.00) and the fact that exenatide CVOT had the largest sample size among the GLP-1 RA CVOT included in the analysis. However, Kelly et al.'s meta-analysis revealed that other GLP-1 RAs were linked to lower cardiovascular event rates in CKD patients, with liraglutide and once-weekly semaglutide showing the greatest absolute reductions [22].